BridgeBio Oncology Therapeutics, Inc.
NASDAQBridgeBio Oncology Therapeutics heads into the back half of 2026 with a fresh Street endorsement pulling against a persistently elevated short score — the tension between analyst conviction and bearish positioning is the defining feature of the stock right now. The most concrete development this week is JP Morgan's initiation of coverage with an Overweight rating and a $27 price…
Snapshot as of 11 Aug 2026
BridgeBio Oncology Therapeutics heads into the back half of 2026 with a fresh Street endorsement pulling against a persistently elevated short score — the tension between analyst conviction and bearish positioning is…
BridgeBio Oncology Therapeutics heads into its May 13 earnings print with a striking gap between Wall Street's conviction and the market's recent drift. The analyst picture is unambiguously positive. Seven firms carry…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BBOT — free to start on ORTEX.
Sign up for free →Open BBOT on ORTEX